Oncotelic Therapeutics Q4 2025 Earnings Results & Report

Oncotelic Therapeutics EPS Results

• Actual EPS: $0.59
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A
• EPS Beat Rate: 3 of last 7 quarters

Oncotelic Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oncotelic Therapeutics (OTCMKTS:OTLC) is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and other serious diseases. The company’s research has centered on RNA-based medicines and treatments designed to target biological pathways involved in tumor growth, immune regulation and disease progression.

Its lead product candidate, OT-101, is an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2), a signaling protein associated with tumor development and immune suppression. OT-101 has been evaluated in clinical studies involving cancers such as glioblastoma, pancreatic cancer and melanoma. The company has also pursued additional oncology and infectious-disease programs, although the status of individual programs may change as development progresses.

Oncotelic Therapeutics was formerly known as Mateon Therapeutics and adopted its current name as it expanded its focus on oncology and related therapeutic technologies. The company has been associated with Dr. Vuong Trieu, who has served in senior executive and leadership roles. Its activities have primarily involved research, clinical development and collaborations intended to advance its drug candidates in the United States and international markets.